期刊文献+

健康查体在胰腺癌早期发现及预后方面的作用研究 被引量:1

Role of health screening for early detection and prognosis estimation in pancreatic cancer
下载PDF
导出
摘要 目的:评估健康查体在胰腺癌早期发现及预后方面的作用。方法:于2003年5月—2008年5月到山东大学齐鲁医院健康体检中心查体的人群中,随机抽取20位诊断为胰腺癌的患者(体检组)。再随机抽取同期至该院门诊就诊的40位胰腺癌患者(门诊组),对2组患者进行回顾性对比研究。结果:体检组根治性切除率明显高于门诊组(P=0.011)。体检组中位生存期明显高于门诊组(P<0.01),然而2组患者3年存活率差异无统计学意义(P>0.05)。在体检组中,无症状患者较有症状患者具有更高的根治率和更长的生存期,但差异无统计学意义(P>0.05)。结论:健康查体可以提高胰腺癌的根治性切除率和中位生存时间,然而,并不能延长患者的长期生存期。 Objective: To evaluate the usefulness of health screening for early detection and improved prognosis in pancreatic cancer.Methods: Between 2003 May and 2008 May,Twenty patients diagnosed with pancreatic cancer were randomly selected from the health promotion center(HPC).During the same period,40 patients diagnosed with pancreatic cancer were randomly selected at the out patient clinic(OPC) for comparison.Results: The curative resection rate was higher in the HPC group than in the OPC group(P=0.011).The median survival was longer in the HPC group than in the OPC group(P〈0.01).However,there was no significant difference in the 3-year survival rate between the two groups(P〉0.05).Asymptomatic patients in the HPC group showed better curative resection and survival rates than symptomatic patients.Conclusions: Health screening is somewhat helpful for improving the curative resection rate and median survival of patients with pancreatic cancer.However,the benefit of this method in improving long-term survival is limited.
出处 《中国现代普通外科进展》 CAS 2012年第9期695-698,共4页 Chinese Journal of Current Advances in General Surgery
关键词 胰腺肿瘤 健康查体 早期发现 预后 Pancreatic neoplasms Health Screening. Early detection Prognosis
  • 相关文献

参考文献13

  • 1Chang DK, Merrett ND, Biankin AV, et al. Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem [J]. J Gastroenterol Hepatol, 2008,23 ( 7 Pt 1 ): 1036-1045.
  • 2Chari ST. Detecting early pancreatic cancer: problems and prospects [J]. Semin Oncol, 2007,34(4):284-294.
  • 3Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric as- say for a monoclonal antibody-defined tumor marker, CA 19-9 [J]. Clin Chem, 1983,29(3):549-552.
  • 4Sohn TA, Yeo C J, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indica- tors[J]. J Gastrointest Surg, 2000,4(6):567-579.
  • 5Ariyama J, Suyama M, Ogawa K, et al. The detection and prognosis of small pancreatic carcinoma[J]. Int J Pancreatol, 1990,7 ( 1-3 ):37-47.
  • 6Canto MI. Strategies for screening for pancreatic adenocarcinoma in high-risk patients[J]. Semin Oncol, 2007,34(4):295-302.
  • 7Kim B J, Lee KT, Moon TG, et al. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects [J]. Dig Liver Dis, 2009,41 (5):364-369.
  • 8Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymp- tomatic population[J].J Gastroenterol Hepatol, 2004,19(2):182-186.
  • 9Lee JK. Screening and diagnosis for pancreatic cancer [J]. Korean J Gastroenterol, 2008,51 (2):84-88.
  • 10Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeu- tic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer[J].Oncology, 2006,70(4):255-264.

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部